The design of a decision aid about diabetes medications for use during the consultation with patients with type 2 diabetes

Maggie Breslin, Rebecca J. Mullan, Victor M. Montori

Research output: Contribution to journalArticle

109 Scopus citations

Abstract

Objective: To describe the process used to develop a medication choice decision aid (DA) for patients with type 2 diabetes. Methods: We developed the DA through active collaboration with patients, clinicians, and designers, direct observations of clinical encounters, literature review, and collaborative development of design criteria. Insights from these processes informed the iterative creation of prototypes that were reviewed and field tested in actual consultations. Results: The goal of the DA was to facilitate a conversation between the clinician and the patient about diabetes medication options. Four iterations of the DA were developed and field-tested before arriving at issue cards that organized the data for five medications around glucose control, hypoglycemia, weight changes, daily routine, self-monitoring and side effects. These cards successfully generated conversations during consultations. An ongoing clinical trial will determine if this DA affects patient adherence and outcomes. Conclusions: A collaboratively developed DA designed to create a conversation about diabetes medications may lead to more patient-centered treatment choices. Practice implications: If effective, this DA could replace disease-centered treatment algorithms for patient-centered conversations that enhance the management of patients with type 2 diabetes.

Original languageEnglish (US)
Pages (from-to)465-472
Number of pages8
JournalPatient Education and Counseling
Volume73
Issue number3
DOIs
StatePublished - Dec 1 2008

Keywords

  • Clinical decision making
  • Diabetes mellitus
  • Patient decision aids

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'The design of a decision aid about diabetes medications for use during the consultation with patients with type 2 diabetes'. Together they form a unique fingerprint.

  • Cite this